Northbound Therapeutics Inc is categorized under Research and Development Laboratories in Oklahoma City, OK .
Northbound Therapeutics Inc was established in 0, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Research and Development Laboratories business, which does work in the B2B market, and is classified as a Research and Development Laboratories, under code number 541712 by the NAICS.
If you are seeking more information, feel free to contact Kris Vermelis at the company’s single location by writing to 940 Sl Young Boulevard, Oklahoma City, Oklahoma OK 73104 or by phoning (405) 818-0967. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Northbound Therapeutics Inc |
| Contact Person: | Kris Vermelis |
| Address: | 940 Sl Young Boulevard, Oklahoma City, Oklahoma 73104 |
| Phone Number: | (405) 818-0967 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Research and Development Laboratories |
| SIC Code: | 8731 |
| NAICS Code: | 541712 |
| Share This Business: |
Northbound Therapeutics Inc was started in 0 to provide professional Research and Development Laboratories under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Kris Vermelis for inquiries that concern Northbound Therapeutics Inc by calling the company number (405) 818-0967, as your correspondence is most welcome. Additionally, the physical location of the single location of Northbound Therapeutics Inc can be found at the coordinates as well as the street address 940 Sl Young Boulevard in Oklahoma City, Oklahoma 73104.
For its online presence, you may visit Northbound Therapeutics Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.